查詢結果分析
相關文獻
- Efficacy of Streptokinase and Heparin in the Treatment of Deep Vein Tnrombosis and Subsequent Follow Up of Pulse Volume Recorder Assessment
- The Role of Heparin in Treatment of Purpura Fulminans: Experience in Four Cases
- Corneal Opacity and Congenital Glaucoma Associated with Massive Heparan Sulfaturia: Report of One Case
- Heparin Immobilization onto Polyurethane Surfaces and Their Characterization
- 肝素及Ticlopidine於犬血液透析之抗凝研究
- 肝素及低分子量肝素對急性肺栓塞的治療
- The Influence of Intra-Graft Heparin Injection on the Survival of Composite Grafts
- A Comparative Study of Urokinase and Heparin in the Treatment of Deep Vein Thrombosis
- Evaluation of a Heterologous Pericardium Immobilized with Heparin as a Vascular Patch in a Canine Model
- 犬血液透析時血液流速與肝素劑量之相關研究(1)
頁籤選單縮合
| 題 名 | Efficacy of Streptokinase and Heparin in the Treatment of Deep Vein Tnrombosis and Subsequent Follow Up of Pulse Volume Recorder Assessment=鏈球激酶及肝素治療深部靜脈栓塞症之療效並應用脈量記錄儀的追蹤評估 |
|---|---|
| 作 者 | 賴曉亭; | 書刊名 | 中華民國外科醫學會雜誌 |
| 卷 期 | 20:3 1987.05[民76.05] |
| 頁 次 | 頁202-209 |
| 分類號 | 416.264 |
| 關鍵詞 | 鏈球激酶; 肝素; 深部靜脈栓塞症; 脈量記錄儀; |
| 語 文 | 英文(English) |
| 中文摘要 | 深部靜脈栓塞造成日後血栓後症候群的致病率非常高,我們已完成分別使用鏈球激酶及肝素治療38位患者共42肢體深部靜脈栓塞的研究。深部靜脈栓塞主要依臨床上的症候並經脈量記錄儀及靜脈血管攝影證實。其中11位患者是接受鏈球激酶治療,有9位男性及2位女性,平均年齡55.3±9.2歲。僅兩位患者(占18%)日後發生血栓後症後群,另1例在開側肢體又復發深部靜底栓塞。有27位患者共31肢體接受肝素治療,有23位男性及4位女性,平均年齡是57.29±11.02歲。有24個肢體(占77.3%)日後發生血詮後症後群,其中三人發生嚴重肢體慢性潰瘍。 此類鏈球激酶及肝素治療兩組在深部靜脈功能性血流力學改變情況應用脈量記錄儀的結果如下:最大靜脈流出量(MVO)是30.11±7.2對17.71±6.8 mm/sec.(P<0.0005),分段靜脈容量(SVC)是46.5±4.89對37.42±13.43 mm(P<0.025),靜脈脈量總分是3.6±2.2對5.58±2.13(P<0.005)。這兩組治療結果不同,極具有明顯統計學意義存在。在鏈球激酶的早期治療下,明顯的降低深部靜脈阻力,減低靜脈高壓及達到幾乎正常的深部靜脈血流力學因而可說在治療深部靜脈俟塞供用鏈球激酶的結果是優於肝素。 |
| 英文摘要 | A prospective study comparing streptokinase and heparin tberapy was completed in 38 patients with 42 limbs showing DVT. DVT. was diagnosed according to the clinical symptoms of 3 to 30 days' duration and was proven by pulse volume recorder and ascending venography. The 11 patients with 11 limbs receiving streptokinase had a mean age of 55.3±9.2 years. Two patients (18%) developed postphlebitic syndrome and one developed repeated DVT in the same leg during follow-up. The 27 patients with 31 limbs receiving heparin therapy had a mean age of 57.29±11.02 years. Twenty-four limbs (77.3%) developed postphlebitic syndrome, three bad serious signs with leg venous ulceration. In addition to the comparison of streptokinase and heparin therapy, the results of functional hemodynamic status of the deep venous system showed the following: Maximal venous outflow 30.11±7.2 to 17.7l±6.8 mm/sec. (P<0.0005), segmental venous capacitance 46.5±4.89 to 37.42±13.43 mm (p<0.025), pulse volume total score 3.6±2.2 to 5.58±2.13(P<0.005). These results show that streptokinase can prevent subsquent venous hypertension, markedly decreasing deep venous resistance and normalizing the deep venous hemodynamic status after treatment. We conclude that streptokinase is superior to heparin in the treatment of DVT. |
本系統中英文摘要資訊取自各篇刊載內容。